<DOC>
	<DOC>NCT01217125</DOC>
	<brief_summary>The purpose of this study is to determine whether rapamycin is safe and effective in the treatment of renal angiomyolipomas in patients with tuberousclerosis.</brief_summary>
	<brief_title>Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Angiomyolipoma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Diagnosis of tuberousclerosis Angiomyolipoma &gt;2cm age&gt;10 years Creatinine &gt;4 No recent AML bleeding No hepatic abnormalities (liver tests 2fold) Hematocrit&lt;27% Thrombocytopenia (&lt;100.000/mm3) Leukopenia (&lt;3000/mm3) Ischemic cardiopathy Recent surgery (2 months prior to enrollment) Pregnancy Serum cholesterol over 7.8 mmol/l or hypertriglyceridemia fasten(&gt;4.6 mmol/l) non controlled with drugs malignancy in the previous 2 years allergy to macrolides</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>tuberousclerosis, angiomyolipoma, rapamycin</keyword>
</DOC>